4th Modern Drug Discovery and Development Summit

GTCbio's 4th Modern Drug Discovery and Development Summit (M3D) will be held on October 15-17, 2008 in San Diego, California. Registration will allow you unlimited access to 6 tracks, 6 mini sessions, 3 short symposia and plenary presentations including the following areas:

6 Tracks

  • Biological Therapeutics
  • Translational Medicine
  • Partnering, Licensing & Outsourcing
  • Drug Design & Lead Discovery
  • Emerging Targets
  • Pharmacokinetics & Pharmacodynamics

3 Short Symposia

  • Regulations & Policy in Drug Development
  • Stem Cells as A Tool for Drug Discovery
  • Imaging Technologies

Over 150 leading industrial and academic experts will present at this three-day summit. M3D will offer an in-depth examination of the challenges involved in the dynamic and ever-changing field of drug discovery and development. It will bring researchers, lab directors/managers, and industry executives the critical scientific, technology, and business coverage that they need.

This conference is designed for

  • Research & Development Professionals
  • Project Managers, Group Leaders and Directors
  • Presidents, Vice Presidents, and CEOs
  • Manufacturers and Marketers
  • Global Project Managers and Strategic Planners
  • Business Development and Licensing Executives
  • Venture Capitalists and Entrepreneurs
  • Academic Researchers and Medical Directors
  • Government Representatives

Dedicated Networking events have been incorporated to enhance the exchange of information between technology developers and end-users. In addition, M3D will provide a great opportunity for companies to expose products and services. Sponsorship and exhibiting opportunities are available in a range of levels, which can be tailored to fit your needs.

For further information and registration, please visit: http://gtcbio.com/conferenceDetails.aspx?id=110

Most Popular Now

Lilly will supply an additional 150,000 doses of b…

Eli Lilly and Company (NYSE: LLY) announced a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab for approximately...

Bayer to sell men's health product Nebido™ to Grün…

Bayer and Grünenthal have entered into a definitive agreement regarding the sale of Bayer's men's health product Nebido™ (testosterone undecanoate), for a purchase price ...

Pfizer and BioNTech complete submission to Europea…

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced they have completed a submission to the European Medicines Agency (EMA) for an Omicron-adapted biva...

The fourth COVID-19 vaccine reduces the risk of de…

A new study by Tel Aviv University and Ben Gurion University of the Negev, in collaboration with the Israeli Ministry of Health, has found that the fourth COVID-19 vaccin...

Vaccine protection against COVID-19 short-lived, b…

Since COVID-19 vaccines first became available to protect against infection and severe illness, there has been much uncertainty about how long the protection lasts, and w...

AstraZeneca to acquire TeneoTwo and its clinical-s…

AstraZeneca announced an agreement to acquire TeneoTwo, Inc. (TeneoTwo)i, including its Phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, currently under evaluatio...

Demonstration of a potent, universal coronavirus m…

The SARS-CoV-2 that causes COVID-19 has killed 6.3 million people worldwide since 2019, painfully highlighting the vulnerability of humanity to novel coronaviruses. Re...

Research shows investigational drug fosters nerve …

Scientists from the University of Birmingham have shown that a brain-penetrating candidate drug currently in development as a cancer therapy can foster regeneration of da...

NIH launches clinical trial of mRNA Nipah virus va…

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has launched an early-stage clinical trial evaluating an inv...

Anti-inflammatory compound shows potential in trea…

An anti-inflammatory compound may have the potential to treat systemic inflammation and brain injury in patients with severe COVID-19 and significantly reduce their chanc...

Vaccine-induced immune response to omicron wanes s…

Although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, antibody levels decrease substan...

SARS-CoV-2 hijacks nanotubes between neurons to in…

COVID-19 often leads to neurological symptoms, such as a loss of taste or smell, or cognitive impairments (including memory loss and concentration difficulties), both dur...